Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a research note issued on Thursday, Benzinga reports. They currently have a $14.00 price objective on the stock. Chardan Capital’s target price indicates a potential upside of 92.84% from the company’s current price.

Separately, HC Wainwright started coverage on shares of Coya Therapeutics in a research report on Monday, September 16th. They issued a “buy” rating and a $18.00 target price for the company.

Coya Therapeutics Price Performance

Shares of NASDAQ:COYA traded up $0.52 on Thursday, hitting $7.26. The company’s stock had a trading volume of 58,290 shares, compared to its average volume of 71,780. The company has a market capitalization of $110.50 million, a PE ratio of -9.95 and a beta of 0.46. The company has a 50-day simple moving average of $6.97 and a 200 day simple moving average of $7.05. Coya Therapeutics has a 1 year low of $4.40 and a 1 year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Monday, August 12th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $3.43 million for the quarter. On average, equities research analysts expect that Coya Therapeutics will post -1.27 earnings per share for the current fiscal year.

Institutional Trading of Coya Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GHP Investment Advisors Inc. bought a new stake in shares of Coya Therapeutics in the 3rd quarter worth approximately $169,000. Renaissance Technologies LLC bought a new stake in Coya Therapeutics in the second quarter worth $101,000. Gilbert & Cook Inc. purchased a new stake in Coya Therapeutics during the second quarter valued at about $61,000. Finally, Vanguard Group Inc. grew its stake in shares of Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after buying an additional 750,338 shares during the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.